DOCSLIB.ORG

SWL CCG Commissioned Pbr Excluded Drug/Device List 2020/2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

SWL Commissioning Principles for PbR Excluded Drugs / Devices 2020-2021 APPENDIX 1: SWL CCG Commissioned PbR excluded drugs / devices list 2020-2021 (version 1- 23/01/2020 (subject to in-year change - awaiting publication of 2020/21 National Tarif) Last updated for 2020/21 and approved by SWL Medicines Commissioning Group: 23 01 2020 Added / altered due to changes in 2020/21 National Tariff: currencies and prices (not yet ListsFor latest all 2020-21 version PbR see: excluded www.swlmcg.nhs.uk drugs and devices for which CCGs have commissioning responsibility available- update to follow) PbR excluded drugs/ devices commissioned by NHS England (NHSE) are not included (see Added / altered due to to changes in NHSE commissioning policy 15.0 (compared to v14.1)- http://www.england.nhs.uk/commissioning/spec-services/key-docs) no changes required In this document adults are classified as anyone attending adult services (usually 18 years or over) Devices Drug/Device type Alternative name PBR Category Indication NICE TA/Policy Management strategy SWL Potentially Notes CCGs prescribed by GPs via shared care Abaloparatide Eladynos® Drugs affecting bone Post-menopausal NICE TA due, date TBC IFR (Tick box form- No Not licensed in UK metabolism osteoporosis Not routinely commissioned until Notification within 2 weeks if (launch plan: terminated) approved by NICE approved by NICE) NHSE is responsible for: - Male osteoporosis - Juvenile osteoporosis Abatacept Orencia® Cytokine modulators Juvenile Arthritis (adults): NICE TA373 (Dec 2015) Tick box form- No NHSE is responsible for: -Polyarticular Notification within 2 weeks -Juvenile Arthritis (paediatric) NHS England E03X04 (Jul 2015): E03/P/d biologics for Juvenile Idiopathic Arthritis in Children and Adults Abatacept Orencia® Cytokine modulators Other indications (adults) Not routinely commissioned IFR No NHSE is responsible for: used in CCG commissioned -Juvenile Arthritis (paediatric services) service -Paediatric indications (where adult TA available) Abatacept Orencia® Cytokine modulators Psoriatic Arthritis (adults) NICE TA568 (March 2019)- IFR No terminated Not routinely commissioned Abatacept Orencia® Cytokine modulators Rheumatoid Arthritis - after NICE TA195 (Aug 2010) Tick box form- No failure of anti-TNF (adults) Notification within 2 weeks Abatacept Orencia® Cytokine modulators Rheumatoid Arthritis (adults) NICE TA375 (Jan 2016) Tick box form- No Notification within 2 weeks Abicipar pegol Subfoveal choroidal Wet age-related macular NICE TA due, date TBC IFR (Tick box form- No Not yet licensed in UK neovascularisation degeneration (wet-AMD) Not routinely commissioned until Notification within 2 weeks if (launch plan: 2020) approved by NICE approved by NICE) Adalimumab Biosimilars: Cytokine modulators Ankylosing Spondylitis NICE TA383 (Feb 2016) Tick box form- No Idacio® (adults) Notification within 2 weeks Amgevita® As per Framework Agreement for the supply of Adalimumab Humira® Injection, Reference number: CM/PHR/19/5575 Adalimumab Biosimilars: Cytokine modulators Axial Spondyloarthritis (non- NICE TA383 (Feb 2016) Tick box form- No Idacio® radiographic) (adults) Notification within 2 weeks Amgevita® As per Framework Agreement for the supply of Adalimumab Humira® Injection, Reference number: CM/PHR/19/5575 1 of 26 Abaloparatide Eladynos® Drugs affecting bone Post-menopausal NICE TA due, date TBC IFR (Tick box form- No Not licensed in UK metabolism osteoporosis Not routinely commissioned until Notification within 2 weeks if (launch plan: terminated) approved by NICE approved by NICE) NHSE is responsible for: - Male osteoporosis - Juvenile osteoporosis Adalimumab Biosimilars: Cytokine modulators Crohn's Disease (adults) NICE TA187 (May 2010) Tick box form- No Idacio® Notification within 2 weeks Amgevita® As per Framework Agreement for the supply of Adalimumab Humira® Injection, Reference number: CM/PHR/19/5575 Adalimumab Biosimilars: Cytokine modulators Juvenile Arthritis (adults): NICE TA373 (Dec 2015) Tick box form- No NHSE is responsible for: Idacio® -Polyarticular Notification within 2 weeks -Juvenile Arthritis (paediatric) Amgevita® -Enthesis-related NHS England E03X04 (Jul 2015): E03/P/d biologics for Humira® Juvenile Idiopathic Arthritis in Children and Adults As per Framework Agreement for the supply of Adalimumab Injection, Reference number: CM/PHR/19/5575 Adalimumab Biosimilars: Cytokine modulators Other indications (adults) Not routinely commissioned IFR No NHSE is responsible for: Idacio® used in CCG commissioned -Behcets syndrome Amgevita® service As per Framework Agreement for -Hidradenitis Suppurativa the supply of Adalimumab -Juvenile Arthritis (paediatric) Humira® Injection, Reference number: -Plaque psoriasis (paediatric) CM/PHR/19/5575 -Paediatric indications (where adult TA available) -Uveitis (adults) Adalimumab Biosimilars: Cytokine modulators Psoriasis (adults) NICE TA146 (Jun 2008) Tick box form- No Idacio® Notification within 2 weeks Amgevita® As per Framework Agreement for the supply of Adalimumab Humira® Injection, Reference number: CM/PHR/19/5575 Adalimumab Biosimilars: Cytokine modulators Psoriatic Arthritis (adults) NICE TA199 (Aug 2010) Tick box form- No Idacio® Notification within 2 weeks Amgevita® As per Framework Agreement for the supply of Adalimumab Humira® Injection, Reference number: CM/PHR/19/5575 Adalimumab Biosimilars: Cytokine modulators Rheumatoid Arthritis - after NICE TA195 (Aug 2010) Tick box form- No Idacio® failure of anti-TNF (adults) Notification within 2 weeks Amgevita® As per Framework Agreement for the supply of Adalimumab Humira® Injection, Reference number: CM/PHR/19/5575 2 of 26 Abaloparatide Eladynos® Drugs affecting bone Post-menopausal NICE TA due, date TBC IFR (Tick box form- No Not licensed in UK metabolism osteoporosis Not routinely commissioned until Notification within 2 weeks if (launch plan: terminated) approved by NICE approved by NICE) NHSE is responsible for: - Male osteoporosis - Juvenile osteoporosis Adalimumab Biosimilars: Cytokine modulators Rheumatoid Arthritis (adults) NICE TA375 (Jan 2016) Tick box form- No Idacio® Notification within 2 weeks Amgevita® As per Framework Agreement for the supply of Adalimumab Humira® Injection, Reference number: CM/PHR/19/5575 Adalimumab Biosimilars: Cytokine modulators Ulcerative Colitis (moderate NICE TA329 (Feb 2015) Tick box form- No Idacio® to severely active) (adults) Notification within 2 weeks Amgevita® As per Framework Agreement for the supply of Adalimumab Humira® Injection, Reference number: CM/PHR/19/5575 Aflibercept Eylea® Subfoveal choroidal Choroidal neovascularisation NICE TA486 (Nov 2017) Tick box form- No neovascularisation (pathological myopia) Notification within 2 weeks Aflibercept Eylea® Subfoveal choroidal Diabetic retinopathy Not routinely commissioned IFR No Not yet licensed in UK neovascularisation (launch plan: TBC) Aflibercept Eylea® Subfoveal choroidal Macular oedema (branch NICE TA409 (Oct 2016) Tick box form- No neovascularisation retinal vein occlusion) Notification within 2 weeks Aflibercept Eylea® Subfoveal choroidal Macular oedema (central NICE TA305 (Feb 2014) Tick box form- No neovascularisation retinal vein occlusion) Local care pathway Notification within 2 weeks Aflibercept Eylea® Subfoveal choroidal Macular oedema (diabetic) NICE TA346 (Jul 2015) Tick box form- No neovascularisation Notification within 2 weeks Aflibercept Eylea® Subfoveal choroidal Other indications used in Not routinely commissioned IFR No NHSE is responsible for: neovascularisation CCG commissioned service -Cancer Aflibercept Eylea® Subfoveal choroidal Wet age-related macular NICE TA294 (Jul 2013) Tick box form- No neovascularisation degeneration (wet-AMD) Local care pathway Notification within 2 weeks Aganirsen Subfoveal choroidal Corneal neovascularisation Not routinely commissioned IFR No Not yet licensed in UK neovascularisation (associated with keratoplasty (launch plan: TBC) rejection) Alicaforsen Camligo® Novel so no group name Pouchitis Not routinely commissioned IFR No Not yet licensed in UK agreed (launch plan: 2021) Alirocumab Praluent® Lipid regulating drugs Dyslipidaemia Not routinely commissioned IFR No Alirocumab Praluent® Lipid regulating drugs Hypercholesterolaemia NICE TA393 (Jun 2016) Tick box form- Yes (primary) and dyslipidaemia Notification within 2 weeks (mixed) Alitretinoin Toctino® Skin Conditions Severe chronic hand eczema NICE TA177 (Aug 2009) Tick box form- No Notification within 2 weeks Alpha-1 antitrypsin Glassia® Drugs used in metabolic Alpha-1 antitrypsin deficiency Not routinely commissioned IFR No Not yet licensed in UK disorders (launch plan: 2021) Amikacin- liposomal Arikayce® Antibacterial Drugs Nontuberculous Not routinely commissioned IFR No Not yet licensed in UK mycobacterial lung disease (launch plan: 2020) caused by Mycobacterium NHSE is responsible for: Avium Complex (MAC) -only -Cystic fibrosis when delivered via nebulisation/inhalation 3 of 26 Abaloparatide Eladynos® Drugs affecting bone Post-menopausal NICE TA due, date TBC IFR (Tick box form- No Not licensed in UK metabolism osteoporosis Not routinely commissioned until Notification within 2 weeks if (launch plan: terminated) approved by NICE approved by NICE) NHSE is responsible for: - Male osteoporosis - Juvenile osteoporosis Anakinra Kineret® Cytokine modulators Juvenile Arthritis (adults) NHS England E03X04 (Jul Blank Tick Box Form No NHSE is responsible for: 2015): E03/P/d biologics for -Juvenile Arthritis (paediatric) Juvenile Idiopathic Arthritis in Children
Recommended publications
  • WO 2015/063180 Al 7 May 2015 (07.05.2015) P O P C T

    WO 2015/063180 Al 7 May 2015 (07.05.2015) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/063180 Al 7 May 2015 (07.05.2015) P O P C T (51) International Patent Classification: (74) Agent: WILLIAMS, Rachel; Novozymes Biopharma UK A61K 39/00 (2006.01) C07K 16/00 (2006.01) Ltd., Castle Court, 59 Castle Boulevard, Nottingham Not A61K 39/395 (2006.01) tinghamshire NG7 1FD (GB). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/EP2014/073261 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) International Filing Date: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 29 October 2014 (29.10.2014) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (26) Publication Language: English MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (30) Priority Data: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 13 190750.3 29 October 2013 (29. 10.2013) EP SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 14166865.7 2 May 2014 (02.05.2014) EP TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant: NOVOZYMES BIOPHARMA DK A S (84) Designated States (unless otherwise indicated, for every [DK/DK]; Krogshoejvej 36, DK-2880 Bagsvaerd (DK).
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies

    Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies

    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011

    Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011

    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
  • Oral Anticoagulants

    Oral Anticoagulants

    4/26/2018 Disclosure • Kelsey Gander, PharmD, BCACP Direct Oral Anticoagulants: – Declares no financial relationships pertinent to this session When to Use and How to Choose – Declares off-label use of medication will not be discussed during this presentation. Kelsey Gander, PharmD, BCACP Minnesota Academy of Physician Assistants Conference May 11th, 2018 Abbreviations Objectives • DOAC= direct oral anticoagulant 1) Compare and contrast the efficacy and safety • VTE= venous thromboembolism • DVT= deep vein thrombosis of direct oral anticoagulants (DOACs) to • PE= pulmonary embolism warfarin • A-fib, AF= atrial fibrillation 2) Identify which anticoagulant would be most • ESRD= end stage renal disease appropriate for a given patient • ACC= American College of Cardiology • AHA= American Heart Association 3) Recognize when it would not be appropriate • HRS= Heart Rhythm Society to use a DOAC • BID= twice daily Appropriate Abbreviations Patient Case JJ is a 66 y/o male who was hospitalized for pulmonary • NOAC embolism and initiated on anticoagulant therapy one week – Novel Oral Anticoagulant ago. – Chief complaint: – Non-Vitamin K Oral Anticoagulant • Presents to clinic today for INR check, post-hospital discharge follow- up • TSOAC – Past medical history: • Hypertension, hyperlipidemia, osteoarthritis, erectile dysfunction, – Target Specific Oral Anticoagulant BPH, type 2 diabetes, peripheral artery disease – Home medications • DOAC • Acetaminophen 650mg po every 6 hours PRN – Direct Oral Anticoagulant • Diazepam 5mg po at bedtime PRN anxiety
  • 76. Which of the Following Is Incorrect Based on the 2018 ASRA Checklist for Managing Local Anesthetic Systemic Toxicity?

    76. Which of the Following Is Incorrect Based on the 2018 ASRA Checklist for Managing Local Anesthetic Systemic Toxicity?

    76. Which of the following is incorrect based on the 2018 ASRA Checklist for managing Local Anesthetic Systemic Toxicity? A. The upper limit of lipid emulsion dosing is 12mL/kg B. Monitoring should be at least 4-6 hours after a cardiovascular event or at least 2 hours after a limited CNS event C. 20% lipid emulsion should be used as the initial drug at the first sign of a serious LAST Event D. Epinephrine doses of > 1mcg/kg are recommended 77. Which of the following statements is NOT true with regard to the management of new oral anticoagulants? A. Rivaroxaban (Xarelto) and Apixaban (Eliquis) should be held for at least 72 hours prior to neuraxial block B. Dabigatran (Pradaxa) should be held for 24 to 48 hours prior to neuraxial block in a patient with a compromised GFR C. Dabigatran can be reversed by the monoclonal antibody idarucizumab D. Factor Xa inhibitors, Rivaroxaban and Apixaban, can be effectivelY reversed with andexanet alfa 78. Which answer the correct spread of local anesthetic for an Erector Spinae Plane Block performed at the T5 level? A. Spread between the erector spinae muscle and rhomboid muscle B. Spread lateral to the transverse process, superficial to the erector spinae muscle C. Spread deep to the erector spinae muscle at the transverse process D. Spread deep to the costotransverse ligament, pushing the pleura ventrallY 79. When assessing the lungs with ultrasound, which of the following signs are suggestive a pneumothorax: A. Absence of lung sliding B. Presence of “comet tails” C. Absence of a “lung point” D.
  • Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories

    Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories

    bioRxiv preprint doi: https://doi.org/10.1101/572958; this version posted March 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Title: Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories. Authors: Konrad Krawczyk1*, Matthew Raybould2, Aleksandr Kovaltsuk2, Charlotte M. Deane2 1 NaturalAntibody, Hamburg, Germany 2 Oxford University Department of Statistics, Oxford, UK *Correspondence to [email protected] Abstract: Recently it has become possible to query the great diversity of natural antibody repertoires using Next Generation Sequencing (NGS). These methods are capable of producing millions of sequences in a single experiment. Here we compare Clinical Stage Therapeutic antibodies to the ~1b sequences from 60 independent sequencing studies in the Observed Antibody Space Database. Of the 242 post Phase I antibodies, we find 16 with sequence identity matches of 95% or better for both heavy and light chains. There are also 54 perfect matches to therapeutic CDR-H3 regions in the NGS outputs, suggesting a nontrivial amount of convergence between naturally observed sequences and those developed artificially. This has potential implications for both the discovery of antibody therapeutics and the legal protection of commercial antibodies. Introduction Antibodies are proteins in jawed vertebrates that recognize noxious molecules (antigens) for elimination. An organism expresses millions of diverse antibodies to increase the chances that some of them will be able to bind the foreign antigen, initiating the adaptive immune response.
  • Question of the Day Archives: Monday, December 5, 2016 Question: Calcium Oxalate Is a Widespread Toxin Found in Many Species of Plants

    Question of the Day Archives: Monday, December 5, 2016 Question: Calcium Oxalate Is a Widespread Toxin Found in Many Species of Plants

    Question Of the Day Archives: Monday, December 5, 2016 Question: Calcium oxalate is a widespread toxin found in many species of plants. What is the needle shaped crystal containing calcium oxalate called and what is the compilation of these structures known as? Answer: The needle shaped plant-based crystals containing calcium oxalate are known as raphides. A compilation of raphides forms the structure known as an idioblast. (Lim CS et al. Atlas of select poisonous plants and mushrooms. 2016 Disease-a-Month 62(3):37-66) Friday, December 2, 2016 Question: Which oral chelating agent has been reported to cause transient increases in plasma ALT activity in some patients as well as rare instances of mucocutaneous skin reactions? Answer: Orally administered dimercaptosuccinic acid (DMSA) has been reported to cause transient increases in ALT activity as well as rare instances of mucocutaneous skin reactions. (Bradberry S et al. Use of oral dimercaptosuccinic acid (succimer) in adult patients with inorganic lead poisoning. 2009 Q J Med 102:721-732) Thursday, December 1, 2016 Question: What is Clioquinol and why was it withdrawn from the market during the 1970s? Answer: According to the cited reference, “Between the 1950s and 1970s Clioquinol was used to treat and prevent intestinal parasitic disease [intestinal amebiasis].” “In the early 1970s Clioquinol was withdrawn from the market as an oral agent due to an association with sub-acute myelo-optic neuropathy (SMON) in Japanese patients. SMON is a syndrome that involves sensory and motor disturbances in the lower limbs as well as visual changes that are due to symmetrical demyelination of the lateral and posterior funiculi of the spinal cord, optic nerve, and peripheral nerves.
  • Tables-Of-Phase-3-Mabs.Pdf

    Tables-Of-Phase-3-Mabs.Pdf

    Table 3. Monoclonal antibodies in Phase 2/3 or 3 clinical studies for cancer indications Most advanced Primary sponsoring company INN or code name Molecular format Target(s) phase Phase 3 indications Therapeutic area Janssen Research & Development, LLC JNJ-56022473 Humanized mAb CD123 Phase 2/3 Acute myeloid leukemia Cancer Murine IgG1, Actinium Pharmaceuticals Iomab-B radiolabeled CD45 Phase 3 Acute myeloid leukemia Cancer Humanized IgG1, Seattle Genetics Vadastuximab talirine ADC CD33 Phase 3 Acute myeloid leukemia Cancer TG Therapeutics Ublituximab Chimeric IgG1 CD20 Phase 3 Chronic lymphocytic leukemia Cancer Xencor XMAB-5574, MOR208 Humanized IgG1 CD19 Phase 2/3 Diffuse large B-cell lymphoma Cancer Moxetumomab Murine IgG1 dsFv, AstraZeneca/MedImmune LLC pasudotox immunotoxin CD22 Phase 3 Hairy cell leukemia Cancer Humanized scFv, Viventia Bio Oportuzumab monatox immunotoxin EpCAM Phase 3 Bladder cancer Cancer scFv-targeted liposome containing Merrimack Pharmaceuticals MM-302 doxorubicin HER2 Phase 2/3 Breast cancer Cancer MacroGenics Margetuximab Chimeric IgG1 HER2 Phase 3 Breast cancer Cancer Gastric cancer or gastroesophageal junction Gilead Sciences GS-5745 Humanized IgG4 MMP9 Phase 3 adenocarcinoma; ulcerative colitis (Phase 2/3) Cancer; Immune-mediated disorders Depatuxizumab Humanized IgG1, AbbVie mafodotin ADC EGFR Phase 2/3 Glioblastoma Cancer AstraZeneca/MedImmune LLC Tremelimumab Human IgG2 CTLA4 Phase 3 NSCLC, head & neck cancer, bladder cancer Cancer NSCLC, head & neck cancer, bladder cancer, breast AstraZeneca/MedImmune
  • Immunfarmakológia Immunfarmakológia

    Immunfarmakológia Immunfarmakológia

    Gergely: Immunfarmakológia Immunfarmakológia Prof Gergely Péter Az immunpatológiai betegségek döntő többsége gyulladásos, és ennek következtében általában szövetpusztulással járó betegség, melyben – jelenleg – a terápia alapvetően a gyulladás csökkentésére és/vagy megszűntetésére irányul. Vannak kizárólag gyulladásgátló gyógyszereink és vannak olyanok, amelyek az immunreakció(k) bénításával (=immunszuppresszió révén) vagy emellett vezetnek a gyulladás mérsékléséhez. Mind szerkezetileg, mind hatástanilag igen sokféle csoportba oszthatók, az alábbi felosztás elsősorban didaktikus célokat szolgál. 1. Nem-szteroid gyulladásgátlók (‘nonsteroidal antiinflammatory drugs’ NSAID) 2. Kortikoszteroidok 3. Allergia-elleni szerek (antiallergikumok) 4. Sejtoszlás-gátlók (citosztatikumok) 5. Nem citosztatikus hatású immunszuppresszív szerek 6. Egyéb gyulladásgátlók és immunmoduláns szerek 7. Biológiai terápia 1. Nem-szteroid gyulladásgátlók (NSAID) Ezeket a vegyületeket, melyek őse a szalicilsav (jelenleg, mint acetilszalicilsav ‘aszpirin’ használatos), igen kiterjedten alkalmazzák a reumatológiában, az onkológiában és az orvostudomány szinte minden ágában, ahol fájdalom- és lázcsillapításra van szükség. Egyes felmérések szerint a betegek egy ötöde szed valamilyen NSAID készítményt. Szerkezetük alapján a készítményeket több csoportba sorolhatjuk: szalicilátok (pl. acetilszalicilsav) pyrazolidinek (pl. fenilbutazon) ecetsav származékok (pl. indometacin) fenoxiecetsav származékok (pl. diclofenac, aceclofenac)) oxicamok (pl. piroxicam, meloxicam) propionsav
  • The Two Tontti Tudiul Lui Hi Ha Unit

    The Two Tontti Tudiul Lui Hi Ha Unit

    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
  • Four-Factor Prothrombin Complex Concentrate Improves Thrombin

    Four-Factor Prothrombin Complex Concentrate Improves Thrombin

    Schenk et al. Thrombosis Journal (2018) 16:1 DOI 10.1186/s12959-017-0158-9 RESEARCH Open Access Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial Bettina Schenk1* , Stephanie Goerke2,3, Ronny Beer4, Raimund Helbok4, Dietmar Fries1 and Mirjam Bachler1,5 Abstract Background: Direct oral anticoagulants (DOACs) pose a great challenge for physicians in life-threatening bleeding events. The aim of this study was to test the efficacy of reversing the DOAC rivaroxaban using four-factor PCC (prothrombin complex concentrate), a non-specific reversing agent. Methods: Patients with life-threatening bleeding events during rivaroxaban treatment were included and administered 25 U kg−1 of PCC. Blood samples were collected immediately prior to as well as after PCC treatment at predefined time intervals. The primary endpoint was defined as the difference in thrombin generation (TG) parameters ETP (endogenous thrombin potential) and Cmax (peak thrombin generation) prior to and ten minutes subsequent to PCC treatment. Results: Thirteen patients, of whom the majority suffered from intra-cranial haemorrhage (ICH) or subdural haemorrhage (SDH), were included and administered PCC. The results show that the ETP (TG) significantly (p = 0.001) improved by 68% and Cmax (TG) by 54% (p = 0.001) during PCC treatment. In addition, the Quick value (prothrombin time: QuickPT) significantly improved by 28% and the activated partial thromboplastin time (aPTT) was PT decreased by 7% ten minutes after PCC administration. Cmax was reduced at baseline, but not ETP, aPTT or Quick . Lag time until initiation (TG, tlag), thromboelastometry clotting time (CTEXTEM) and time to peak (TG, tmax) correlated best with measured rivaroxaban levels and were out of normal ranges at baseline, but did not improve after PCC administration.
  • Pharmacotherapy Pearls for Emergency Neurological Life Support Theresa Human1*, Eljim Tesoro2* and Sarah Peacock3

    Pharmacotherapy Pearls for Emergency Neurological Life Support Theresa Human1*, Eljim Tesoro2* and Sarah Peacock3

    Neurocrit Care https://doi.org/10.1007/s12028-019-00830-4 PHARMACOTHERAPY Pharmacotherapy Pearls for Emergency Neurological Life Support Theresa Human1*, Eljim Tesoro2* and Sarah Peacock3 © 2019 Neurocritical Care Society Abstract The appropriate use of medications during Emergency Neurological Life Support (ENLS) is essential to optimize patient care. Important considerations when choosing the appropriate agent include the patient’s organ function, medication allergies, potential adverse drug efects, drug interactions, critical illness, and age-related pathophysi- ologic changes. Medications used during ENLS include hyperosmolar therapy, antiseizures, antithrombotics, antico- agulant reversal hemostatic agents, antishivering agents, neuromuscular blockers, antihypertensive agents, sedatives, vasopressors inotropes, and antimicrobials. This chapter focuses on key pharmacokinetic and pharmacodynamic characteristics, advantages and disadvantages, and clinical pearls of these therapies, thereby providing practitioners with essential drug information to optimize pharmacotherapy in acutely ill neurocritical care patients. Keywords: ENLS, Pharmacotherapy, Medication, Adverse drug event, Drug interaction Introduction provider optimize medication management in the acute Neurocritical care patient management is highly com- period of neurologic injury. plicated, especially when trying to optimize therapy dur- ing the acute injury. Pharmacologic management must Chapter Outline be carefully considered in order to minimize cognitive • Hyperosmolar